CD4+ T cell‐mediated HER‐2/neu‐specific tumor rejection in the absence of B cells

Open Access
Publisher Website
Google Scholar
Abstract
HER‐2/neu (HER‐2) is a cell surface proto‐oncogene that is often overexpressed in carcinomas. Passive administration of anti‐HER‐2 antibodies in breast cancer patients has achieved promising results, but less is known about the role of antibodies in active immunization. We asked whether B cells/antibodies are needed for tumor immunity induced by plasmid (HER‐2 and GM‐CSF) immunization. HER‐2 specific tumor immunity relied completely on both CD4+ and CD8+ T cells. IFN‐γ, and to a lesser extent IL‐4, seemed to be crucial cytokines during tumor rejection. Protection was associated with production of anti‐HER‐2 IgG antibodies in B cell competent mice. After immunization, however, B cell‐deficient mice rejected HER‐2‐expressing tumors as efficiently as control littermates. We conclude that T cells are the main effector cells in DNA vaccine induced immunity against HER‐2 and that anti HER‐2 antibodies are not necessary to elicit a protective anti tumor immune response in this model.
Funding Information
  • Swedish Cancer Society
  • Cancer Society in Stockholm
  • King Gustaf V Jubilee Fund
  • European Community
  • Swedish Research Council
  • Wallenberg Foundation
  • Swedish Foundation for Strategic Research
  • Deutsche Krebshilfe
  • Dr. Mildred-Scheel-Stiftung, e.V.